D
Dorothee Nickles
Researcher at Genentech
Publications - 32
Citations - 7639
Dorothee Nickles is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & T cell. The author has an hindex of 17, co-authored 32 publications receiving 5113 citations. Previous affiliations of Dorothee Nickles include University of California, San Francisco & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
In depth comparison of an individual’s DNA and its lymphoblastoid cell line using whole genome sequencing
Dorothee Nickles,Lohith Madireddy,Shan Yang,Pouya Khankhanian,Steve Lincoln,Stephen L. Hauser,Jorge R. Oksenberg,Sergio E. Baranzini +7 more
TL;DR: The results suggest that, at this level of resolution, the LCL is genetically indistinguishable from its genomic counterpart and therefore their use in clinical research is not likely to introduce a significant bias.
Journal ArticleDOI
Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models
Huizhong Xiong,Stephanie Mittman,Ryan Rodriguez,Patricia Pacheco-Sanchez,Marina Moskalenko,Yagai Yang,Justin Elstrott,Alex T. Ritter,Sören Müller,Dorothee Nickles,Teresita L. Arenzana,Aude-Hélène Capietto,Lélia Delamarre,Zora Modrusan,Sascha Rutz,Ira Mellman,Rafael Cubas +16 more
TL;DR: It is reported that among CD8+ T cells in commonly used syngeneic tumor models, the coexpression of inhibitory receptors PD-1, LAG3, and TIM3 defined a group of highly activated and functional effector cells in syngenetic tumor models.
Journal ArticleDOI
The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis
Nicole Fewings,Prudence N. Gatt,Fiona C. McKay,Grant P Parnell,Stephen D. Schibeci,J. Edwards,Monica A. I. Basuki,Anita Goldinger,Marzena J. Fabis-Pedrini,Marzena J. Fabis-Pedrini,Allan G. Kermode,Clara P. Manrique,Jacob L. McCauley,Dorothee Nickles,Sergio E. Baranzini,Therese Burke,Steve Vucic,Graeme J. Stewart,David R. Booth +18 more
TL;DR: It is shown expression is partially heritable, relatively stable over time, predominantly in plasmacytoid dendritic cells and non-classical monocytes, and that levels of ZMIZ1 protein expression are reduced in MS.
Journal ArticleDOI
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
David F. McDermott,Mahrukh Huseni,Michael B. Atkins,Robert J. Motzer,Brian I. Rini,Bernard Escudier,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,James A. Reeves,Mario Sznol,John D. Hainsworth,W. Kimryn Rathmell,Walter M. Stadler,Thomas E. Hutson,Martin Gore,Alain Ravaud,Sergio Bracarda,Cristina Suarez,Riccardo Danielli,Viktor Gruenwald,Toni K. Choueiri,Dorothee Nickles,Suchit Jhunjhunwala,Elisabeth Piault-Louis,Alpa Thobhani,Jiaheng Qiu,Daniel S. Chen,Priti S. Hegde,Christina Schiff,Gregg Fine,Thomas Powles +31 more
TL;DR: In the version of this article originally published, there was an error in Fig. 2n where the top line of the HR comparison chart originally was Atezo + bev vs sun.
Journal ArticleDOI
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation.
Jason E. Long,Matthew Wongchenko,Dorothee Nickles,Wei-Jen Chung,Bu-Er Wang,Johannes Riegler,Ji Li,Qingling Li,Wendy Sandoval,Jeffrey Eastham-Anderson,Zora Modrusan,Teemu T. Junttila,Richard A.D. Carano,Oded Foreman,Yibing Yan,Melissa R. Junttila +15 more
TL;DR: Although treatment-relapsed tumors remained genetically stable, they converged on a shared resistance phenotype characterized by dramatic changes in tumor cell differentiation state, immune infiltration, and extracellular matrix (ECM) composition.